GPC Biotech to Host Investor Event in Chicago on June 4th during ASCO
Annual Meeting
Martinsried/Munich (Germany) and Princeton, N.J., May 29, 2007 - GPC
Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ:
GPCB) today announced that the Company will host an investor event on
Monday, June 4, 2007, 6:00-7:30 pm Central Time (June 5, 2007 at 1 am
CEST) during the ASCO Conference in Chicago, IL. The event will be
webcast live and will be accessible through the GPC Biotech Web site
at www.gpc-biotech.com. A replay will also be available via the Web
site.
Cora Sternberg, M.D., FACP, Chief of the Department of Medical
Oncology at the San Camillo and Forlanini Hospitals, Rome, Italy is a
confirmed guest speaker for the event and will discuss the
investigational drug, satraplatin as well as lead a general
discussion regarding the treatment of hormone-refractory prostate
cancer. Dr. Sternberg is a leading authority in the treatment of
genitourinary cancers and one of the principal investigators of the
SPARC registrational trial. Dr. Sternberg will give a podium
presentation on data from the SPARC trial at the ASCO Annual Meeting
Members of the GPC Biotech senior management team will also be
available to discuss corporate activities.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs.
GPC Biotech's lead product candidate satraplatin is currently under
review by the U.S. FDA for hormone-refractory prostate cancer
patients whose prior chemotherapy has failed. Satraplatin was
in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also
developing a monoclonal antibody with a novel mechanism-of-action
against a variety of lymphoid tumors, currently in Phase 1 clinical
development, and has ongoing drug development and discovery programs
that leverage its expertise in kinase inhibitors. GPC Biotech AG is
headquartered in Martinsried/Munich (Germany), and has a wholly owned
U.S. subsidiary headquartered in Princeton, New Jersey. For
additional information, please visit GPC Biotech's Web site at
www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech
AG, including statements about the status of the FDA review process.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. In particular, there can
be no guarantee that additional information relating to the safety,
efficacy or tolerability of satraplatin may be discovered upon
further analysis of data from the SPARC trial or analysis of
additional data from other ongoing clinical trials for satraplatin.
Furthermore, we cannot guarantee that satraplatin will be approved
for marketing in a timely manner, if at all, by regulatory
authorities nor that, if marketed, satraplatin will be a successful
commercial product. We direct you to GPC Biotech's Annual Report on
Form 20-F for the fiscal year ended December 31, 2005 and other
reports filed with the U.S. Securities and Exchange Commission for
additional details on the important factors that may affect the
future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.
Satraplatin has not yet been approved by the FDA in the U.S., the
EMEA in Europe or any other regulatory authority and no conclusions
can or should be drawn regarding its safety or effectiveness. Only
the relevant regulatory authorities can determine whether satraplatin
is safe and effective for the use(s) being investigated.
Contacts:
GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
usinvestors@gpc-biotech.com
--- End of Message ---
GPC Biotech AG
Fraunhoferstr. 20 Martinsried
WKN: 585150; ISIN:
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX,
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin Bremen,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Geregelter Markt in Frankfurter Wertpapierbörse;